News for DexCom, Inc. (DC4.DE)

Insulet Corporation (NASDAQ: PODD), the global leader in [url="]tubeless insulin pump[/url] technology, is excited to announce that the Omnipod® 5 App for iPh

On May 30, 2025, Goldman Sachs analyst Kate McShane initiated coverage on DexCom (DXCM), a leading player in the continuous glucose monitoring sector. The firm

Goldman Sachs has recently begun coverage on DexCom, identifying a Buy rating with a target price of $104. This optimistic outlook is part of a comprehensive an

DexCom (DXCM), a leader in diabetes management systems, has received an updated evaluation from Citigroup analyst Joanne Wuensch. On May 22, 2025, Wuensch maint

Below is the April 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.

DexCom, Inc. (DXCM), a leader in continuous glucose monitoring systems, has announced a significant change in its executive leadership. Effective May 9, 2025,

DexCom, Inc. (DXCM) recently held its Annual Meeting on May 8, 2025, where several significant proposals were approved by the stockholders. The meeting saw th

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs are […]

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc.

We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.

On May 5, 2025, Barclays analyst Matt Miksic announced a price target adjustment for DexCom (DXCM). The price target has been raised from the previous $90.00 to

The company’s first-quarter sales hit $1.04 billion, surpassing the anticipated $1.02 billion.

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday. Shares of Trupanion, Inc. TRUP rose sharply during Friday's session afte...

Shares of DexCom Inc (DXCM) surged 5.21% in mid-day trading on Apr 24. The stock reached an intraday high of $70.55, before settling at $70.35, up from its

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board membe

PR NewswireNEW YORK, April 22, 2025 NEW YORK, April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether c

Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASD